[Federal Register Volume 60, Number 117 (Monday, June 19, 1995)]
[Notices]
[Page 32016]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-14898]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Opportunity for Licensing: Pharmaceutical Preparations Containing
Cyclodextrin Derivatives
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institutes of Health (NIH), Department of Health
and Human Services, seeks licensee(s) for U.S. Patent 4,727,064,
entitled ``Pharmaceutical Preparations Containing Cyclodextrin
Derivatives,'' which issued February 23, 1988. This invention describes
a method of improvement of pharmaceutical preparations which comprises
the addition of crystalline drugs with substantially low solubility to
cyclodextrin compounds which are water soluble, have the ability to
form inclusion complexes with the drugs in question, and are
intrinsically amorphous and substantially decrease the tendency of the
drug to crystallize.
This U.S. Patent had been exclusively licensed to Pharmatec Inc.
and Cyclex Inc. (see Federal Register of September 10, 1987--52 FR
34268) by the National Technical Information Service (NTIS). The period
of general exclusivity provided under the NTIS agreements has expired
and the patent is now available for licensing. NTIS has transferred
custody of this case to NIH and NIH has the right to grant nonexclusive
or exclusive licenses to this patent in most fields of use. In
particular, NIH can grant an exclusive license for the use of
cyclodextrin technology in combination with ``drug actives'' that are
approved for a particular use by the Food and Drug Administration (FDA)
if the drug active itself or its FDA-approved use is covered by a U.S.
patent.
NIH intends to grant the selected firm(s) royalty-bearing
license(s) to practice the inventions embodied in U.S. Patent 4,727,064
in the U.S. for all or some of the available fields of use. The patent
rights in these inventions have been assigned to the United States of
America.
SUPPLEMENTARY INFORMATION: The NIH seeks licensee(s), who in accordance
with requirements and regulations governing the licensing of
government-owned inventions (37 CFR Part 404), have the most
meritorious plan for the development of the cyclodextrin technology to
a marketable status to meet the needs of the public and with the best
terms for the NIH. The criteria that NIH will use to evaluate license
applications will include, but not be limited to those set forth by 37
CFR 404.7(a)(1)(ii)-(iv).
ADDRESSES: Requests for a copy of the patent, license application form,
or other questions and comments concerning the licensing of this
technology should be directed to: Carol C. Lavrich, Technology
Licensing Specialist, Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7735 ext 287; fax: 301/402-
0220.
Dated: June 5, 1995.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 95-14898 Filed 6-16-95; 8:45 am]
BILLING CODE 4140-01-P
